Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

Using a combination of Stemoxydine, minoxidil, dutasteride, and keto shampoo to achieve extreme hair and beard growth. The user has experienced positive results with terminal hairs at the hairline and an increase in density to their stubble after several weeks of use.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The post discusses a hair loss treatment routine involving dutasteride, topical finasteride, rosemary oil/onion juice/coffee solution, and stemoxydine. The user emphasizes the importance of consistency, realistic expectations, and a healthy lifestyle.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

A user shared their positive experience with hair regrowth using finasteride 1.25 mg daily and dermastamping every two weeks. They reported no side effects and noticed regrowth after about three months.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.